C&EN

How T regs fueled a new class of immunology companies

But the Darwin team didn’t last much longer. In 1996, a company called Chiroscience Group acquired Darwin, and in 1999 ...
TMCnet

Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control

PALO ALTO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a new class of allergy therapeutics, today announced its launch with a $70 million Series A ...
Nasdaq

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with ...
Seeking Alpha

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a ...

Nobel Prize in Physiology or Medicine Is Awarded for Work on Immune Systems

Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi were awarded the prize for research showing how the body regulates its ...
BioWorld

Kymera Therapeutics unveils first-in-class oral degrader immunology programs

Kymera Therapeutics Inc. has unveiled two new first-in-class oral degrader programs for immune-mediated diseases: KT-621, a STAT6 degrader, and KT-294, a TYK2 degrader.
Seeking Alpha

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics ...
PharmiWeb

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief ...

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive OfficerSeries A ...
Morningstar

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases HiFiBiO Therapeutics, a ...